Guaifenesin (60mg) + Diethylcarbamazine (100mg) + Chlorpheniramine Maleate (2mg) (Medical Monograph)

Overview

A fixed-dose combination (FDC) drug primarily used in the Indian market for the symptomatic treatment of cough and respiratory allergies, with an added anti-filarial component. It combines an expectorant (Guaifenesin), an anti-filarial/anti-inflammatory agent (Diethylcarbamazine), and a first-generation antihistamine (Chlorpheniramine Maleate). This combination is specifically formulated to address cough with thick mucus, allergic symptoms, and underlying conditions like tropical pulmonary eosinophilia (TPE) which are prevalent in certain Indian regions.

Guaifenesin enhances the output of respiratory tract fluid by reducing the adhesiveness and surface tension of secretions, facilitating their removal. Diethylcarbamazine citrate exhibits microfilariacidal action by altering the microfilarial surface structure, making them susceptible to host defense mechanisms; it also has anti-inflammatory properties. Chlorpheniramine Maleate competitively antagonizes histamine at the H1 receptor, relieving allergic symptoms like rhinorrhea and sneezing.